Evommune Inc. (EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, has a pair of clinical trial catalysts to watch in the coming months.
The company has two investigational drugs in clinical development, namely EVO756 and EVO301.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com